Cardiovascular Complications and COVID-19 (CovCardioVasc-Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

198 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-28

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF

NCT04344327

Infection Viral Infection, Hospital COVID

COMPLETED

Cardiac Biomarkers and Mortality in Critically Ill Patients With SARS-CoV-2 (COVID-19)

NCT04641988

COVID-19

COMPLETED

Prognostic and Clinical Impact of Cardiovascular Involvement in Patients With COVID-19

NCT04624503

Covid19 Myocardial Injury Cardiovascular Diseases +2 more

UNKNOWN

EPIdemiological Approaches to the Cardiovascular Consequences of COVID-19

NCT04498091

Acute Myocardial Infarction

UNKNOWN

MYocardial DOmmages Related to COVID-19

NCT04498065

Covid19 Non Ischemic Myocardial Injury Myocardial Infarction +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID Acute Coronary Syndrome Myocardial Infarction Myocarditis Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with cardiovascular complications

Patients presenting with cardiomyopathies or venous thromboembolism

No interventions assigned to this group

Patients without cardiovascular complications

Patients without cardiomyopathies or venous thromboembolism

No interventions assigned to this group

Intensive Care Unit patients

Patients admitted in intensive care unit

No interventions assigned to this group

Hospital Ward patients

Patients admitted in hospital ward

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be included